Weekly ReportMay 5–11, 2026
Sepsis, week 19 edition
We read 209 papers and selected 3.
Summary
This week’s sepsis literature highlights convergent advances in metabolic and mitochondrial mechanisms, early diagnostic/definition changes for lung injury, and epithelial-derived therapeutic targets. A high-quality preclinical/transcriptomic study nominates the GATM–PDK4 metabolic axis for protecting proximal tubules in sepsis-AKI. Expanded ARDS criteria using SpO2:FiO2 enable earlier case capture with preserved prognostic value, and epithelial FGF20 emerges as a translational candidate that stabilizes barrier function while suppressing intrapulmonary procoagulant signaling.
Selected Articles
1. GATM alleviates sepsis-induced acute kidney injury via PDK4-mediated glycolytic reprogramming in renal tubular epithelial cells.
Cross-dataset discovery and preclinical validation identify GATM as a protective regulator in sepsis-associated AKI. GATM overexpression suppresses PDK4-driven aerobic glycolysis, reduces lactate, increases ATP production, and mitigates tubular and mitochondrial injury in vivo and in vitro; PDK4 overexpression reverses these effects, positioning the GATM–PDK4 axis as a targetable metabolic checkpoint.
Impact: Reveals a novel metabolic checkpoint with mechanistic rescue experiments (PDK4 overexpression) and multimodal validation, offering a concrete target for metabolic modulation in sepsis-AKI.
Clinical Implications: Although preclinical, targeting PDK4 or augmenting GATM suggests a strategy to restore mitochondrial energetics and prevent/treat sepsis-associated AKI; translation requires dose-finding, biomarkers, and safety evaluation.
Key Findings
- GATM identified across four GEO datasets as downregulated in proximal tubule cells during S-AKI and LPS-stimulated HK-2 cells.
- AAV-mediated GATM overexpression improved renal function, reduced KIM-1/IL-6/Caspase-3/4-HNE, and mitigated mitochondrial injury in LPS-induced S-AKI mice.
- GATM overexpression downregulated PDK4 and glycolytic markers (p-PDHA, HK2, LDHA, GLUT1), lowered lactate and increased ATP; PDK4 overexpression abolished these protective effects.
2. Epidemiology of the acute respiratory distress syndrome and the prognostic validity of SpO2:FiO2 under the expanded Global definition.
In a prospective sepsis cohort (n=950), the Global ARDS definition identified more cases and enabled a median 3-hour earlier diagnosis than the Berlin criteria. SpO2:FiO2 (S/F) retained prognostic value for 30-day mortality and moderately correlated with PaO2:FiO2, supporting S/F as an earlier, pragmatic metric for ARDS detection in patients on high-flow devices.
Impact: Directly impacts case ascertainment and timing for ARDS in sepsis by validating the Global definition and S/F ratio, with immediate implications for earlier lung-protective care and trial enrollment criteria.
Clinical Implications: Adopt S/F-based criteria in clinical pathways to detect ARDS earlier—particularly for patients on high-flow nasal cannula—allowing faster implementation of lung-protective strategies and potential earlier inclusion in therapeutic trials.
Key Findings
- Global ARDS definition identified 49% vs 45% with Berlin criteria over 6 days in sepsis (n=950).
- Diagnosis occurred a median of 3.0 hours earlier with the Global definition.
- SpO2:FiO2 predicted 30-day mortality and moderately correlated with PaO2:FiO2.
3. FGF20 activates FGFR1-PI3K-AKT signaling to coordinate barrier integrity and alveolar coagulation in sepsis-induced lung injury.
In CLP-induced sepsis lung injury, recombinant human FGF20 improved 7-day survival, reduced edema and inflammation, and stabilized the alveolar-capillary barrier while suppressing tissue factor and PAI-1 via FGFR1–PI3K–AKT signaling. Human ARDS samples showed reduced FGF20 levels that correlated with worse oxygenation, supporting FGF20 as a mechanistically grounded translational candidate to limit immunothrombotic lung injury.
Impact: Identifies an epithelial-derived integrator (FGF20) that simultaneously preserves barrier architecture and restrains procoagulant programs with survival benefit in vivo and human biomarker correlation—strong translational rationale.
Clinical Implications: FGF20 measurement could aid ARDS risk stratification; early-phase trials of FGF20 agonists or replacement therapy are justified to test barrier-protective and anticoagulant benefits alongside standard lung-protective care.
Key Findings
- Recombinant human FGF20 improved 7-day survival and reduced pulmonary edema and inflammation in CLP rat sepsis-induced lung injury.
- FGF20 via FGFR1–PI3K–AKT suppressed NF-κB activation, downregulated tissue factor and PAI-1, and stabilized junctional proteins (E-cadherin, VE-cadherin, ZO-1) through GSK3β Ser9 phosphorylation.
- FGFR1 or AKT inhibition abrogated both barrier-protective and anticoagulant effects, confirming pathway dependency; human ARDS samples had reduced FGF20 correlating with lower PaO2/FiO2.